鉻（三價鉻） Chromium × 胰島素阻抗
結論：證據支持
鉻 × 胰島素阻抗（IR）的證據以替代指標（HOMA-IR、空腹胰島素）為主，且訊號高度不一致：Asbaghi 2020 (28 RCT) 報告 HOMA-IR 顯著下降但 I²=89.
C 🟠 C 薄弱證據 已發布 ⚠️ medium — moderate promotional content
鉻 × 胰島素阻抗（IR）的證據以替代指標（HOMA-IR、空腹胰島素）為主，且訊號高度不一致：Asbaghi 2020 (28 RCT) 報告 HOMA-IR 顯著下降但 I²=89.9%；Yin & Phung 2015 顯示 picolinate/yeast 對 HbA1c 為陰性；FDA 2005 QHC 明示『關係極不確定』並駁回 6 項擴大宣稱；ADA 明確不推薦、Endocrine Society 沉默不背書、EFSA 直接認定鉻非必需且拒絕大多數宣稱、Cleveland Clinic 對鉻×IR 完全 not_addressed、Harvard 不背書常規補充。
L1 Examine 雖標 B（fuzzy match 自 T2DM 表內 'Insulin Resistance' outcome），但僅 7 RCT/n=450 之 surrogate Small Decrease，且無 dedicated condition entry——B 等級不足以代表 IR 本身的整體證據強度。
綜合判定屬 C（薄弱證據，機轉合理但人體試驗訊號分散）。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.50
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 已發布
信心度
62%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.496
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes
結論：Chromium mono- and combined supplementation significantly improved glycemic control (HbA1c, FPG); evidence for fasting insulin and HOMA-IR less consistent; safety acceptable at studied doses.
前往 PubMed
Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus
結論：Cr yeast, brewer's yeast and Cr picolinate showed no statistically significant effects on HbA1c. Only brewer's yeast showed significant FPG reduction; other chromium forms showed no FPG effect. HOMA-IR was not reported as a primary endpoint.
前往 PubMed
Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
結論：Pooled analysis showed significant HOMA-IR reduction with chromium supplementation (WMD -1.53, 95% CI -2.35 to -0.72, p<0.001) in T2DM, but with very high heterogeneity (I2=89.9%). Effects on FPG, insulin and HbA1c also reached significance with similarly high heterogeneity.
前往 PubMed
Chromium supplementation in women with polycystic ovary syndrome: Systematic review and meta-analysis
結論：HOMA-IR significantly decreased (SMD -0.84, 95% CI -1.30 to -0.38, p=0.0004); however, fasting insulin, FBS, BMI and QUICKI showed no significant change. Total/free testosterone paradoxically increased. Authors conclude chromium 'may not have significant benefits' for PCOS overall.
前往 PubMed
Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis
結論：Chromium picolinate reported as more effective than metformin in reducing HOMA-IR (p<0.00001); improvements in fasting insulin and lipid profile reported, but specific MD/CI for HOMA-IR not provided in abstract. Authors stress need for more trials before dietary guidelines.
前往 PubMed
L4a US FDA
謹慎
One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain. 來源↗
L4b EU EFSA
反對
The Panel concludes that there is no evidence of beneficial effects associated with chromium intake in healthy subjects ... no Average Requirement (AR) and Population Reference Intake (PRI) can be defined; chromium is not an essential nutrient. 來源↗
L4c UK NHS
謹慎
You should be able to get all the chromium you need by eating a varied and balanced diet. Around 25 micrograms of chromium a day should be enough for adults. Having 10mg or less a day of chromium from food and supplements is unlikely to cause any harm. 來源↗
L4d TW TFDA / 衛福部
支持
每日食用量中，其鉻之總含量不得高於200微克 來源↗
L4e WHO
未表態
Chromium[VI] is carcinogenic to humans (Group 1). Metallic chromium and chromium[III] compounds are not classifiable as to their carcinogenicity to humans (Group 3). 來源↗
L5a NIH Office of Dietary Supplements
謹慎
Research suggests that chromium supplementation reduces body weight and body fat percentage to a very small, but statistically significant, extent. However, these effects have little clinical significance. 來源↗
L5b Mayo Clinic
謹慎
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
謹慎
L5e Specialty Society (condition-mapped)
支持
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 中度
低中高
📍立場總覽
台灣社群（PTT Health/MuscleBeach/FITNESS、Dcard、Mobile01）幾乎沒有把「三價鉻」單方用於胰島素阻抗的實測心得；鉻多以糖尿病/血糖複方（如力增飲鉻100）或減脂補劑配方成分出現，鄉民少有針對性辯證，討論量稀薄。
💬社群實感
無共識（社群幾乎沒有將三價鉻單方用於胰島素阻抗的親身實測；多為糖尿病/血糖複方或減脂補劑中的配方成分，無針對性效果回報）
破解迷思 社群最常見的 3 個誤解
✓
事實鉻能直接減肥燃脂（社群與衛教多澄清：研究雖有統計顯著減重但幅度未達臨床意義，主要是業配/減脂補劑話術）
✓
事實鉻補充品可取代Metformin或降血糖藥（社群與藥師強調不能取代正規治療，僅PCOS研究顯示HOMA-IR可能改善）
✓
事實把含鉻血糖複方（如鉻100）當成保健萬靈丹，認為餐後喝就能控糖（鄉民多談飽足感而非實際控糖數據）
🩹 社群通報的副作用
- 與降血糖藥併用恐低血糖（多為轉述藥師/衛教提醒，非鄉民親身回報）
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 力增飲 鉻100（糖尿病/血糖複方，PTT Health 實際提及，主打營養補充與飽足感而非單方降胰島素阻抗）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 強化生活型態介入（飲食加運動，目標減重 5–7%）
- 中等強度規律運動（每週 150 分鐘）
- Metformin（二甲雙胍）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-insulin-resistance-INT-chromium-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "鉻（三價鉻）能改善胰島素阻抗",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}